Pharmaceutical

FDA issues CRL to Orexo’s NDA for opioid overdose medication

The US FDA has issued a complete response letter (CRL) to Orexo regarding its NDA for OX124 to counteract opioid overdoses.

Jul 18, 2024 - 04:00
FDA issues CRL to Orexo’s NDA for opioid overdose medication
The US FDA has issued a complete response letter (CRL) to Orexo regarding its NDA for OX124 to counteract opioid overdoses.
Read the original article

Tags:

Previous Article

China NMPA approves Zai Lab-argenx’s efgartigimod alfa for gMG

Next Article

Autoimmune-Stricken Patients Respond to Allogeneic CAR-T Treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

MSD signs Daiichi Sankyo in multibillion dollar deal to develop ADCs

MSD signs Daiichi Sankyo in multibillion dollar deal to...

Oct 21, 2023

How smart hospitals private equity performed in the pha...

Jul 27, 2023

STAT+: Midwest health systems Fairview and Sanford call off $14 billion merger

STAT+: Midwest health systems Fairview and Sanford call...

Jul 28, 2023